New spinal fluid test aims to solve dementia misdiagnosis puzzle

NCT ID NCT07166744

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will test whether measuring a specific abnormal protein (alpha-synuclein) in spinal fluid can reliably distinguish dementia with Lewy bodies (DLB) from Alzheimer's disease. Researchers will collect samples and perform cognitive tests on 286 older adults with suspected DLB or Alzheimer's. A better diagnostic test could prevent dangerous medication errors in DLB patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to a reliable diagnostic test for dementia with Lewy bodies, reducing misdiagnosis and preventing harmful treatments.

What could go wrong

This is an observational study, not a treatment trial. The test may not prove accurate enough in real-world settings, and results may not change clinical practice quickly.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease bipolar disorder corticobasal degeneration disorder depressive disorder frontotemporal dementia Lewy body dementia Lewy Body Disease progressive supranuclear palsy schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.